ConductScience.org, home

Paper41304752

Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions.

Pérez-Ortega HU and 8 others. Pharmaceutics, 2025. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions. Papers, record 41304752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41304752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions.
PubMed
Journal
Pharmaceutics
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.6, provisional
iCite
Revised in PubMed
2025-11-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pérez-Ortega HUHeber Uriel
2Córdova-Espíritu RRRubén Ricardohttps://orcid.org/0009-0001-9038-6749
3Cano-Serrano SSebastian
4García-González EEduardo
5Bravo-Sánchez MGMicael Gerardohttps://orcid.org/0000-0003-3083-4172
6Orozco-Mosqueda MDCMa Del Carmenhttps://orcid.org/0000-0002-4782-9751
7Jiménez-Islas HHugohttps://orcid.org/0000-0002-1084-5520
8Luna-Bárcenas GGabrielhttps://orcid.org/0000-0002-1162-6928
9Villaseñor-Ortega FFranciscohttps://orcid.org/0000-0002-7190-0511

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References185

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130509782Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents.Bioorg Med Chem Lett2019https://conductscience.org/library/papers/30509782PubMed
229844300Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines.Pharmaceuticals (Basel)2018https://conductscience.org/library/papers/29844300PubMed
338534365TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.Cells2024https://conductscience.org/library/papers/38534365PubMed
426679767Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents.Med Princ Pract2016https://conductscience.org/library/papers/26679767PubMed
530858085Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.Nanomedicine2019https://conductscience.org/library/papers/30858085PubMed
640805204Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies.Cancers (Basel)2025https://conductscience.org/library/papers/40805204PubMed
737543063Lipid based formulations as supersaturating oral delivery systems: From current to future industrial applications.Eur J Pharm Sci2023https://conductscience.org/library/papers/37543063PubMed
833163147Functional roles in cell signaling of adaptor protein TRADD from a structural perspective.Comput Struct Biotechnol J2020https://conductscience.org/library/papers/33163147PubMed
923836376Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.Oncol Rep2013https://conductscience.org/library/papers/23836376PubMed
1036705281Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.J Manag Care Spec Pharm2023https://conductscience.org/library/papers/36705281PubMed
1131415916Irinotecan: 25 years of cancer treatment.Pharmacol Res2019https://conductscience.org/library/papers/31415916PubMed
1239061709Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.Diagnostics (Basel)2024https://conductscience.org/library/papers/39061709PubMed
1329520731Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Clin Pharmacokinet2018https://conductscience.org/library/papers/29520731PubMed
1423006513Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.Biochim Biophys Acta2013https://conductscience.org/library/papers/23006513PubMed
1539404324Enhancing the Efficacy of Active Pharmaceutical Ingredients in Medicinal Plants through Nanoformulations: A Promising Field.Nanomaterials (Basel)2024https://conductscience.org/library/papers/39404324PubMed
1633324678Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization.Front Mol Biosci2020https://conductscience.org/library/papers/33324678PubMed
1739201338Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.Int J Mol Sci2024https://conductscience.org/library/papers/39201338PubMed
1837586663A critical review of the novelties in the development of intravenous nanoemulsions.Eur J Pharm Biopharm2023https://conductscience.org/library/papers/37586663PubMed
1927671528Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.Mol Cancer Ther2016https://conductscience.org/library/papers/27671528PubMed
2032531842Multiple roles of caspase-8 in cell death, inflammation, and innate immunity.J Leukoc Biol2021https://conductscience.org/library/papers/32531842PubMed

See all 185 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42924725Epigenetic Landscape and Regulation of Secondary Metabolite Accumulation Implicated in Anticancer and Nutraceuticals.Epigenomes2026https://conductscience.org/library/papers/42924725PubMed
42514944Novel Camptothecin-Based Lipid Conjugated with Steroids and Triterpene Acids: Enhanced Cellular Uptake and Topoismerase I Inhibition.Pharmaceutics2026https://conductscience.org/library/papers/42514944PubMed
41888388Topoisomerase I/II inhibitors: from established drugs to next-generation therapeutics.Inflammopharmacology2026https://conductscience.org/library/papers/41888388PubMed
41872836Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Mol Cancer2026https://conductscience.org/library/papers/41872836PubMed
41754919Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.Pharmaceutics2026https://conductscience.org/library/papers/41754919PubMed
41752469Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions.Molecules2026https://conductscience.org/library/papers/41752469PubMed
41683797Mining the Hidden Pharmacopeia: Fungal Endophytes, Natural Products, and the Rise of AI-Driven Drug Discovery.Int J Mol Sci2026https://conductscience.org/library/papers/41683797PubMed
41599661Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41599661PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41304752

GET https://conductscience.org/api/papers/v1/41304752/references?page=2